Tom 20, Nr 2 (2024)
Inne materiały uzgodnione z Redakcją
Opublikowany online: 2024-08-14
Wyświetlenia strony
102
Wyświetlenia/pobrania artykułu
22
Przegląd piśmiennictwa
DOI: 10.5603/ppn.101452
Pol. Przegl. Neurol 2024;20(2):138-141.
Streszczenie
Brak
Referencje
- Popiel M, Bartosik-Psujek H. Clinical and radiological consequences of delayed therapy escalation in patients with relapsing-remitting multiple sclerosis. Neurol Neurochir Pol. 2024; 58(1): 84–93.
- Johansson E, Alfredsson L, Strid P, et al. Head trauma results in manyfold increased risk of multiple sclerosis in genetically susceptible individuals. J Neurol Neurosurg Psychiatry. 2024; 95(6): 554–560.
- Volk T, Urbach H, Fingerle V, et al. Spectrum of MRI findings in central nervous system affection in Lyme neuroborreliosis. Sci Rep. 2024; 14(1): 12486.
- Zhang X, Wu J, Lin J, et al. Characteristics of recurrence in area postrema-onset NMO spectrum disorder - a retrospective cohort study. BMC Neurol. 2024; 24(1): 165.
- Chaiyanarm S, Satiraphan P, Apiraksattaykul N, et al. Infliximab in neurosarcoidosis: a systematic review and meta-analysis. Ann Clin Transl Neurol. 2024; 11(2): 466–476.
- Roman SN, Sadaghiani MS, Diaz-Arias LA, et al. Quantitative brain F-FDG PET/CT analysis in seronegative autoimmune encephalitis. Ann Clin Transl Neurol. 2024; 11(5): 1211–1223.
- Muñoz-Lopetegi A, Guasp M, Prades L, et al. Spanish anti-LGI1 Encephalitis Study Group. Neurological, psychiatric, and sleep investigations after treatment of anti-leucine-rich glioma-inactivated protein 1 (LGI1) encephalitis in Spain: a prospective cohort study. Lancet Neurol. 2024; 23(3): 256–266.
